| Consolidated Condensed Income Statements | |
| Product revenue | |
| Service revenue | |
| Total revenue | 608.2M |
| Costs of product revenue | |
| Costs of service revenue | |
| Total costs of revenue | 417.7M |
| Gross profit | 190.5M |
| Selling, general and administrative expenses | |
| Research and development expenses | 16.4M |
| Transformation costs | |
| Asbestos-related costs, net | |
| Restructuring and asset impairment charges, net | |
| Operating income | 37.2M |
| Interest and non-operating expenses, net | 2.7M |
| Income from continuing operations before income tax expense | 34.5M |
| Income tax expense | 15M |
| Income from continuing operations | 19.5M |
| (Loss) income from discontinued operations, including tax benefit of $0, $7, $1 and $5, respectively | 1.7M |
| Net income | 20.8M |
| Basic: | |
| Continuing operations | 0.21 |
| Discontinued operations | 0.02 |
| Net income | 0.23 |
| Diluted: | |
| Continuing operations | 0.2 |
| Discontinued operations | 0.02 |
| Net income | 0.22 |
| Weighted average common shares - basic | 92M |
| Weighted average common shares - diluted | 93.2M |
| Cash dividends declared per common share | 0.1 |